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Pulmonary lesions from active tuberculosis patients are thought to contain persistent, nonreplicating bacilli that arise from hy-
poxic stress. Metronidazole, approved for anaerobic infections, has antituberculosis activity against anoxic bacilli in vitro and in
some animal models andmay target persistent, nonreplicating bacilli. In this double-blind, placebo-controlled trial, pulmonary
multidrug-resistant tuberculosis subjects were randomly assigned to receive metronidazole (500 mg thrice daily) or placebo for 8
weeks in addition to an individualized background regimen. Outcomes were measured radiologically (change on high-resolution
computed tomography [HRCT]), microbiologically (time to sputum smear and culture conversion), and clinically (status 6
months after stopping therapy). Enrollment was stopped early due to excessive peripheral neuropathies in the metronidazole
arm. Among 35 randomized subjects, 31 (15 metronidazole, 16 placebo) were included in the modified intent-to-treat analysis.
There were no significant differences by arm in improvement of HRCT lesions from baseline to 2 or 6 months. More subjects in
the metronidazole arm converted their sputum smear (P 0.04) and liquid culture (P 0.04) to negative at 1 month, but these
differences were lost by 2 months. Overall, 81% showed clinical success 6 months after stopping therapy, with no differences by
arm. However, 8/16 (50%) of subjects in the metronidazole group and 2/17 (12%) of those in the placebo group developed pe-
ripheral neuropathy. Subjects who received metronidazole were 4.3-fold (95% confidence interval [CI], 1.1 to 17.1) more likely
to develop peripheral neuropathies than subjects who received placebo. Metronidazole may have increased early sputum smear
and culture conversion but was too neurotoxic to use over the longer term. Newer nitroimidazoles with both aerobic and anaer-
obic activity, now in clinical trials, may increase the sterilizing potency of future treatment regimens.
The nitroimidazole antibiotic class has been used to treat pro-tozoan and anaerobic bacterial infections for over 50 years.
Metronidazole, the most widely used nitroimidazole, is typically
well tolerated at2 g daily (1). Longer-term use for severe infec-
tions is often limited by the development of peripheral neuropa-
thies (2–5), as well as optic neuropathy (6), neutropenia, and cen-
tral nervous system toxicities, including cerebellar ataxia,
encephalopathy, and seizures (5, 7, 8).
Nitroimidazoles have also demonstrated activity under hy-
poxic conditions against Mycobacterium tuberculosis. In vitro,
metronidazole reduced viable counts of M. tuberculosis bacilli by
98% under anaerobic conditions but had no activity under aero-
bic conditions (9). In M. tuberculosis-infected animals, efficacy is
species specific and linked to the presence of hypoxic necrotizing
lesions. For example, metronidazole has no activity in tuberculo-
sis (TB) models in mice (10, 11), which generally do not develop
hypoxic lesions. In contrast, metronidazole has efficacy in rabbits
and nonhuman primates, which develop necrotizing granulomas
that are hypoxic (12, 13). One study from India compared the
addition of metronidazole versus placebo to a background regi-
men in humans for treatment of advanced pulmonary TB. The
authors reported significantly improved sputum quantity reduc-
tion and radiological outcomes at week 4, and clinical responses at
weeks 4 and 8, but no significant differences in sputum culture
conversion rates at week 4, 8, or 12 (14).
The objective of this study was to determine the benefit of metro-
nidazole versus placebo added to an individualized background reg-
imen (IBR) for subjects with pulmonary multidrug-resistant tuber-
culosis (MDR-TB) through changes in high-resolution computed
tomography (HRCT), sputum smear and culture conversion rates,
and final clinical outcomes.
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MATERIALS AND METHODS
Study design. This randomized, double-blind, placebo-controlled phase
II study was conducted at the National Masan Hospital (NMH) in Chang-
won, South Korea, from 2005 to 2012. Subjects 20 years old with spu-
tum smear- and culture-positive pulmonary MDR-TB were enrolled.
Subjects were excluded if they were HIV positive, did not meet specific
baseline laboratory criteria, had a prior adverse reaction to metronidazole
or a similar drug, were unable to abstain from alcohol (an exclusion that
was imposed due to metronidazole’s disulfiram-like effect), or received
14 days of MDR-TB therapy before enrollment. Subjects were random-
ized to add oral metronidazole (500 mg thrice daily) or placebo for 8
weeks to an IBR stratified by ofloxacin resistance (yes/no). The metroni-
dazole dose used was selected based on a literature review of studies using
metronidazole over the longer term. These studies, often performed in in-
flammatory bowel disease patients, used a wide range of dosing but often 500
to 750 mg three times daily. The lower end of this range was selected to try to
reduce toxicities. Individualized background tuberculosis regimens and du-
rations used in this study were consistent with those recommended in World
Health Organization (WHO) guidelines (15). All subjects continued their
IBR for18 months after sputum culture conversion and then were followed
for an additional 6 months after the end of therapy (EOT).
Outcomemeasures. Outcomes were measured radiologically, micro-
biologically, and clinically. The radiological outcomes measured were
changes in lesions associated with active tuberculosis (16) from baseline to
2 and 6 months by pulmonary HRCT, with tuberculosis-related lesions
defined as nodules (2 mm, 2 to 4 mm, and 4 to 10 mm), consolida-
tions, collapse, cavities, fibrosis, bronchial thickening, tree-in-bud opac-
ities, and ground glass opacities. Based on a previous study (17), each CT
scan was divided into six zones (upper, middle, and lower zones of the
right and left lungs) and independently scored for the lesions listed above
by three separate radiologists blinded to the treatment arm. A fourth
radiologist adjudicated any discrepant scores. The HRCT score was deter-
mined by visually estimating the extent of the lesions listed above in each
lung zone as follows: 0 0% involvement; 1 1% to 25% involvement;
2 26% to 50% involvement; 3 51% to 75% involvement; and 4 76%
to 100% involvement. A composite score for each lesion type was calcu-
lated by summing the scores for each specific abnormality in each lung
zone and dividing by the number of zones. Changes in composite scores
measured at 2 and 6 months were compared to baseline. Microbiological
outcomes included time to conversion to negative as measured by sputum
smear and culture (liquid [MB/Bact] and solid [Ogawa] media). The con-
version date was defined as the first date of three consecutive negative tests
at least 1 month apart. The start date was the date of IBR initiation. Mi-
crobiological failure was defined as a patient being persistently culture
positive while on therapy or becoming culture negative (defined by the
conversion date as described above) and then reverting to being persis-
tently culture positive while on therapy. Sporadic single positive cultures
that were negative on repeat sputum culture were not considered failures.
Clinical success was defined as being repeatedly culture negative on ther-
apy and without evidence of disease 6 months after EOT by either micro-
biologic confirmation or a clinical report. Deaths were considered fail-
ures. Those lost to follow-up included subjects who did not complete
therapy and those who successfully completed therapy but could not be
contacted 6 months after EOT.
Adverse eventmonitoring and pharmacokinetics (PK). Subjects un-
derwent baseline and serial safety evaluations (complete blood count,
chemistries, and liver function tests) weekly until week 12, monthly until
week 24, and then every other month until EOT. Clinical exams occurred
monthly until EOT. Adverse events of grade 3, as defined by the DAIDS
toxicity table (http://rsc.tech-res.com/safetyandpharmacovigilance
/gradingtables.aspx), were captured. For peripheral neuropathies, this
was defined as follows:
• Grade 1 (mild): asymptomatic with sensory alteration on examina-
tion or minimal paresthesia causing no or minimal interference
with usual social and functional activities
• Grade 2 (moderate): sensory alteration or paresthesia causing
greater than minimal interference with usual social and functional
activities
• Grade 3 (severe): sensory alteration or paresthesia causing inability
to perform usual social and functional activities
• Grade 4 (potentially life-threatening): disabling sensory alteration
or paresthesia causing inability to perform basic self-care functions
Grade 1 and 2 peripheral neuropathies were also captured due to the
concern for this adverse event in metronidazole-treated subjects.
For pharmacokinetics, blood samples were collected 1 h before the
8:30 a.m. dose for trough plasma concentrations and 3 h after the 1 p.m.
dose for peak plasma concentrations (the third dose was given at 6:30
p.m.) during weeks 1, 4, and 8. Metronidazole concentrations were mea-
sured by adapting and validating a previously described high-perfor-
mance liquid chromatography (HPLC)-mass spectrometry method (3).
The linear trapezoidal equation was used to calculate areas under the
curves (AUCs) from the measured concentration-time data obtained for
peak and trough concentrations as follows: AUC  [(tn  1  tn)/2 
(Cn Cn  1)] where tn and Cn are the time and concentration of the n
th
specimen, respectively.
Study oversight. Informed consent was collected from all partici-
pants. This study was approved by the institutional review boards (IRBs)
of the NMC in South Korea and the National Institute of Allergy and
Infectious Diseases (NIAID) in the United States. A Data and Safety Mon-
itoring Board (DSMB) reviewed the study, at first quarterly and then twice
a year. All serious adverse events were reported to the DSMB and both
IRBs. The study was monitored by an independent clinical research orga-
nization. Metronidazole and the size, shape, and color-matched placebo
were purchased from CJ Cheiljedang Pharma Corp. of South Korea.
Statistics. Analysis was by modified intent to treat (MITT), excluding
four subjects; two were withdrawn prior to receiving study drug, and two
withdrew shortly after receiving the baseline HRCT scan (Fig. 1). Treat-
ment group comparisons were based on a Wilcoxon rank sum test. Fish-
er’s exact test was used to compare proportions across treatment groups.
Comparisons of baseline covariates and treatment outcomes, ignoring
treatment assignment, were evaluated using Fisher’s exact test (for binary
covariates) and Wilcoxon’s rank sum test (for continuous covariates).
The small number of failures (n 4) limited multivariate analyses on the
effect of baseline covariates on outcomes. Time-to-smear and culture-
negative analyses were conducted using Kaplan-Meier curves and log-
rank statistics. Analyses were conducted in Stata version 12.0 and R ver-
sion 2.15.0. Significance was defined at the P 0.05 level.
RESULTS
Study subjects. This study had a planned enrollment of 80 sub-
jects. After 35 were enrolled, the DSMB recommended closing the
study to further enrollment due to excessive peripheral neuropa-
thies in the metronidazole arm. Among the 35 subjects, 17 were
randomized to the metronidazole arm and 18 to the placebo arm
(Fig. 1). Two subjects (one from each arm) were withdrawn before
receiving any study drug. Two additional subjects (one from each
arm) withdrew after receiving only the baseline HRCT scans: one
withdrew due to missing14 days of study drug (protocol with-
drawal criterion), and the other withdrew consent after receiving
10 days of study drug. These four withdrawn subjects were ex-
cluded from the MITT analysis because the primary study end-
points could not be evaluated in them. Of the 31 included subjects,
the median age was 37 years, 81% were male, and the median
body-mass index was 19 (Table 1). The subjects had a median of 2
previous episodes of tuberculosis and were resistant to a median of
4 drugs at baseline. Forty-eight percent had far advanced disease
(defined in Table 1) by chest X-ray, 52% had cavities, and 68% had
Carroll et al.
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bilateral disease. There were no significant differences in baseline
characteristics between the two groups.
Outcomemeasures. The radiologists’ scores for each of the 10
lung lesions seen on the baseline and 2- and 6-month HRCT are
shown in Fig. 2. Although the mean composite score across all
lesions declined over time from baseline (mean, 9.1; standard
error [SE], 0.84) to month 6 (mean, 7.00; SE, 0.69) (P 
0.0001), the differences were not associated with the use of
metronidazole. The mean composite score declined by 19%
from baseline (mean, 8.1; SE, 1.3) to month 6 (mean, 6.6; SE,
1.00) in the metronidazole arm and by 39% from baseline
(mean, 10.1; SE, 1.0) to month 6 (mean, 7.2; SE, 0.9) in the
placebo arm, which was not statistically significant. Time to
sputum smear and culture conversion by Kaplan-Meier analy-
sis is shown in Fig. 3. Overall, the median times to smear con-
version were 19 days for the metronidazole arm and 43.5 days
for the placebo arm (P 0.76); median times to liquid-culture
conversion were 28 days for the metronidazole arm and 66.5
days for the placebo arm (P  0.51); median times to solid-
culture conversion were 21 days for the metronidazole arm and
42.5 days for the placebo arm (P 0.84). A significantly greater
proportion in the metronidazole arm converted their smear
(P 0.04) and liquid cultures (P 0.04) to negative at month
1, but these differences were lost by month 2. There was no
difference in time to culture conversion by arm using solid
medium. In comparing overall clinical outcomes, 80% of sub-
jects in the metronidazole arm and 81% of subjects in the pla-
cebo arm showed clinical success 6 months after EOT (Table 2).
Four subjects (three in the metronidazole arm and one in the
placebo arm) were treatment failures. There were no differ-
ences in treatment outcomes by arm. In a univariate analysis of
baseline characteristics associated with overall clinical out-
comes, treatment-failure subjects (compared to treatment-
success subjects) had significantly more previous episodes of
tuberculosis (P  0.02), had isolates resistant to a larger num-
ber of drugs at baseline (P 0.01), had fewer active drugs used
in treatment regimens (P  0.004), and had isolates with a
greater proportion with fluoroquinolone resistance (P 
0.009). Due to the small number of failure subjects (n  4),
multivariate analyses were not done.
Safety. Adverse events were stratified by days 1 to 60 and
days 60 because metronidazole was used only during the initial
FIG 1 Flow diagram for subjects included in the study.
TABLE 1 Baseline characteristicsa
Patient characteristic
Metronidazole
treatment
(n 15)
Placebo
treatment
(n 16)
Total
(n 31)
Age in yrs, median (IQR) 36 (28, 39) 38 (31, 44) 37 (30, 43)
Male, n (%) 13 (87) 12 (75) 25 (81)
Body-mass index, median (IQR) 19 (18, 20) 19 (18, 22) 19 (18, 21)
Diabetes mellitus, n (%) 1 (7) 2 (13) 3 (10)
Previous TB episodes, median n (IQR) 2 (1, 5) 3 (2, 3) 2 (1, 3)
Resistant drugs, median n (IQR) 4 (3, 6) 5 (4, 6) 4 (4, 6)
Active drugs in regimen, median n (IQR) 4 (4, 5) 5 (4, 5) 5 (4, 5)
Fluoroquinolone resistance, n (%) 5 (33) 6 (38) 11 (35)
Far advanced disease,b n (%) 5 (33) 10 (63) 15 (48)
Cavitary disease by CXR, n (%) 6 (40) 10 (63) 16 (52)
Bilateral disease by CXR, n (%) 9 (60) 12 (75) 21 (68)
a There were no statistical differences in baseline characteristics between the two arms.
CXR, chest X ray.
b “Far advanced tuberculosis” was defined according to the guidelines of the Korea
Centers for Disease Control and Prevention as the presence of disseminated lesions of
slight-to-moderate density exceeding the total volume of one lung, or dense and
confluent lesions exceeding one-third the volume of one lung, or the presence of
cavities greater than 4 cm in diameter.
Metronidazole for Pulmonary MDR-TB
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2 months (Table 3). All adverse events occurred in similar num-
bers between arms except that more peripheral neuropathies oc-
curred in the metronidazole arm (relative risk [RR], 4.3; 95%
confidence interval [CI], 1.1 to 17.1). Half of all subjects who
received metronidazole developed peripheral neuropathy.
Among all 10 neuropathies, 5 were grade 2 (all in the metronida-
zole arm), with the remainder all being grade 1. All neuropathies
either resolved completely or had only minor sequelae (tingling in
toes or soles of feet) at a median of 1,006 days after starting. Twelve
subjects (8 in the metronidazole arm and 4 in the placebo arm)
permanently discontinued the study drug early at a median of 31
days after starting the study drug.
Pharmacokinetics. For most subjects, the variability in expo-
sure between weeks 1, 4, and 8 was low. Overall, the median peak,
trough, and AUC from 0 to 24 h [AUC(0 to 24)] concentration
values were 31.6 g/ml (interquartile range [IQR], 18.0 to 36.7),
24.8 g/ml (IQR, 14.4 to 31.2), and 527 g/ml (IQR, 367 to 813),
respectively. Clinical PK parameters reported in the literature for
metronidazole administered orally at 500 mg were largely ob-
tained from single-dose studies in healthy volunteers (8 to 13 g/
ml) (18, 19). The much higher peaks observed in this patient pop-
ulation could be related to accumulation of metronidazole at the
steady state when administered three times daily, although the
actual values for maximum concentration of drug in serum (Cmax)
administered at 500 mg thrice daily are not available for direct
comparison. Multiple dosing of 400 mg orally provided peak
plasma concentrations of between 11 and 13 g/ml (18). Because
12 g/ml or 70 M metronidazole causes a 98% reduction of
viable bacillus counts under anaerobic conditions in vitro (9),
therapeutic levels were maintained in the plasma in all but two
FIG 2 Box plots showing radiologist reader scores for each of 10 lesions on high-resolution computed tomography scans at baseline and 2 and 6 months. PLA,
placebo; MET, metronidazole. There were no significant differences by arm for any lung lesion at any time point.
Carroll et al.
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patients during the entire dosing interval. Median (IQR) peak
concentrations for those with and without peripheral neuropathy
were 36.7 g/ml (17.7 to 37.6) and 25.5 g/ml (18.1 to 36.2),
respectively. Median (IQR) trough concentrations for those with
and without peripheral neuropathy were 29.4g/ml (12.4 to 34.5)
and 20.2g/ml (14.8 to 29.4), respectively. Median (IQR) AUC(0
to 24) concentrations for those with and without peripheral neu-
ropathy were 569 g/ml (339.5 to 832.5) and 527 g/ml (390 to
787), respectively. There were no statistical differences in peak,
trough, or AUC(0 to 24) levels between subjects with or without
peripheral neuropathy.
DISCUSSION
This study of IBR plus metronidazole versus IBR plus placebo for
the initial 2 months in pulmonary MDR-TB subjects was closed to
enrollment early due to an excess of peripheral neuropathies in the
metronidazole arm. Among 31 subjects in the MITT analysis,
there were no significant differences between arms in radiological
changes by HRCT from baseline to 2 or 6 months. Microbiologi-
cally, sputum smear and liquid culture converted to negative ear-
lier at 1 month in the metronidazole arm but equal numbers con-
verted by 2 months and no differences in culture conversion rates
were seen on solid culture. Clinically, there were no differences in
outcomes between treatment arms 6 months following EOT.
Antituberculosis chemotherapy has traditionally targeted aer-
obic, replicating bacilli identified from sputum. Historically, it
was assumed that these bacilli primarily represented rapidly grow-
ing organisms from the aerobic surface of cavities open to airways.
However, nonreplicating M. tuberculosis bacilli are increasingly
recognized as representing a subpopulation present in sputum
during active disease. Acid-fast bacilli (AFB) in sputum samples
have recently been reported to contain abundant lipid bodies,
intracellular droplets composed of triacylglycerols, thought to be
synthesized under conditions of stress, such as reduced oxygen or
hypoxia (20). M. tuberculosis grown in the laboratory under hy-
poxic conditions enters a nonreplicating persistent state, with ac-
cumulation of triacyglycerols (21). In addition, AFB from sputum
have transcriptional signatures consistent with a hypoxia-induced
state of nonreplicating persistence. The proportion of lipid body-
positive AFB in sputum correlated (R2 0.64;P 0.03) with time
to positivity in liquid cultures, showing that the more nonrepli-
cating persistent bacteria there were, the longer the cultures took
to become positive (20). Mycobacterial cells in vitro have also been
shown to be longer during logarithmic growth and shorter during
stationary phase (22). In another study, bacilli from sputum and
bronchoalveolar lavage (BAL) fluid were compared with bacilli
from cavities of active pulmonary TB patients undergoing lung
surgery. The lengths of M. tuberculosis isolated from sputum and
BAL fluid were consistent with mixtures of logarithmically repli-
cating and nonreplicating bacilli in vitro, whereas bacilli from cav-
ities of resected lung tissue were significantly shorter (P 0.001),
resembling stationary-phase organisms in vitro (23). All of these
characteristics are shared by bacilli adapted to an in vitro model
known as the Wayne model in which M. tuberculosis shows sensi-
tivity to metronidazole (24). Thus, in contrast to what was previ-
ously assumed, a substantial proportion of AFB in sputum likely
arises from lesions in which the bacilli are in a nonreplicating
persistent state due to a local anaerobic microenvironment.
In an attempt to target more specifically these nonreplicating
persistent AFB, we added metronidazole to a standard MDR-TB
FIG 3 Kaplan-Meier plots of time to conversion by sputum smear, liquid
culture, and solid culture stratified by treatment arm.
TABLE 2 Treatment outcomes 6 months after treatment completion
Treatment outcome
No. (%) of patientsa
Metronidazole
treatment
(n 15)
Placebo
treatment
(n 16)
Total
(n 31)
Failure 3 (20) 1 (6) 4 (13)
Success 12 (80) 13 (81) 25 (81)
Lost to follow-up 0 (0) 2 (13) 2 (6)
a No statistically significant differences in outcome by treatment group.
Metronidazole for Pulmonary MDR-TB
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treatment regimen. Because we assumed that these bacilli would
reside in necrotic pulmonary lesions, we carefully examined the
radiologic findings in subjects by arm. Although there were no
significant differences, this is, to our knowledge, the first semi-
quantitative, prospective examination of changes in HRCT
findings in subjects being treated for active tuberculosis. A
more detailed examination of these findings will be reported
later. Surprisingly, our results indicated a more rapid sputum
smear and liquid culture clearance at 1 month, a difference that
disappeared when sputum smear and culture conversion rates
in the control arm caught up. It is not clear if this early micro-
biologic response in the metronidazole arm would have per-
sisted if exposure had not been limited by neurotoxicity. Al-
though metronidazole itself is unlikely to be a clinically useful
drug for the treatment of tuberculosis due to peripheral neu-
ropathies, alternative antibiotics with anaerobic activity that
are better tolerated may still increase the sterilizing potency of
future treatment regimens.
In our study subjects, peripheral neuropathies improved in all
subjects after stopping metronidazole, consistent with a prior re-
port showing that symptoms improved with the reinnervation of
the skin, with small nerve fibers measured by serial biopsy speci-
men after stopping therapy (25). Pharmacokinetic analysis of the
metronidazole dose and interval used demonstrated appropriate
levels, with no correlation between metronidazole peak/trough
concentrations or AUC(0 to 24) and development of peripheral
neuropathy.
The major limitation of our study was the small sample size,
due to enrollment being closed early, limiting our power to draw
definitive conclusions. Although a greater difference between
arms still would not have made metronidazole a viable treatment
option for MDR-TB due to the toxicity, it might have confirmed
more definitively the treatment strategy of using anaerobically
active drugs to treat persistent, nonreplicating bacilli.
The presence of persistent nonreplicating AFB in sputa sug-
gests a much more dynamic environment for anaerobic lesions
than previously thought and highlights the importance of in-
cluding an antibiotic with anaerobic activity in antituberculo-
sis treatment regimens. In our study, metronidazole provided
an apparent early microbiological benefit but continued use of
this drug was limited by neurotoxicity. Newer nitroimidazoles
which have both aerobic and anaerobic activity are now in
development and show promise against M. tuberculosis (26).
PA-824 has demonstrated antituberculosis activity in combi-
nation with other drugs in vitro (27), in mice (28), and in
human early bactericidal activity studies (29, 30), with a phase
II trial now ongoing. Delamanid (OPC-67683), in combination
with an optimized background regimen, has already demon-
strated success compared to placebo in a phase II study in
pulmonary MDR-TB subjects (31, 32). There were no reports
of increased paresthesias in the delamanid arms compared to
the placebo arm in this trial, and a phase III trial is now ongo-
ing. Thus, the nitroimidazoles, particularly the newer and bet-
ter-tolerated ones, have the potential to increase the sterilizing
activity of antituberculosis treatment regimens by attacking
more specifically persistent nonreplicating bacilli, thereby al-
lowing a shorter total treatment duration (13). The pharmaco-
dynamic concept of “sterilizing activity” of a regimen refers to
the ability of a regimen to kill bacilli that contribute to relapse
following discontinuation of therapy (33). Early clinical trials
of tuberculosis included radiologic rates of change as moni-
tored by chest X-ray but failed to come up with a quantitative
measure of the sterilizing potential of regimens. In conclusion,
our results highlight the potential for the newer nitroimidaz-
oles to contribute to treatment regimens with more sterilizing
potency. In future analyses, we will evaluate the role of quan-
titative HRCT response rates in combination with careful bac-
teriology as a potential radiological biomarker (radiomarker)
of treatment outcomes.
TABLE 3 All adverse events of grade 3 and above and peripheral neuropathies of grades 1 and 2 that were reported
Adverse event(s)
During metronidazole treatment phase (days 1–60) After metronidazole treatment phase (days 60)
No. (%) of
patients receiving
metronidazole
(n 16)
No. (%) of
patients receiving
placebo (n 17)
Relative risk
(95% CI)
No. (%) of
patients receiving
metronidazole
(n 16)
No. (%) of
patients receiving
placebo (n 17)
Relative risk
(95% CI)
Aspergilloma 1 (6.3) 0
Diarrhea 1 (6.3) 1 (5.9) 1.1 (0.1–15.6)
Fracture 0 1 (5.9) 0
Gastritis 1 (6.3) 0
Hemoptysis 1 (6.3) 0
Hepatitis/elevated
transaminases
1 (6.3) 0 1 (6.3) 0
Hypercholesterolemia 0 1 (5.9) 0
Hyperglycemia 0 1 (5.9) 0 1 (6.3) 1 (5.9) 1.1 (0.1–15.6)
Hyperuricemia 3 (18.8) 3 (17.6) 1.1 (0.2–4.5) 3 (18.8) 2 (11.8) 1.6 (0.3–8.3)
Hypokalemia 1 (6.3) 0
Myalgia(s) 0 1 (5.9) 0
Nausea 1 (6.3) 0
Peripheral neuropathy 8 (50.0) 2 (11.8) 4.3 (1.1–17.1)
Pneumothorax 0 1 (5.9) 0
Rash 0 1 (5.9) 0
Seizure 2 (12.5) 1 (5.9) 2.1 (0.2–21.2) 1 (6.3) 0
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